

PATENT

Our Docket: P-LJ 4377

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:
Rajotte et al.

Serial No.: 09/676,475

Filed: September 29, 2000

For: METHODS FOR IDENTIFYING LUNG HOMING MOLECULES USING MEMBRANE DIPEPTIDASE

U.S. Patent and Trademark Office Box Sequence, P.O. Box 2327 Arlington, VA 22202

Sir:

Examiner: M. Moran Group Art Unit: 1631 RECEIVED

TECH CENTER 1600/2900

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

\*EXPRESS MAIL\* MAILING LABEL NUMBER: EL 857044

DATE OF DEPOSIT: November 20, 2002

I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING 12/402 DEPOSITED WITH THE UNITED STATES POSTAL SERVICE "EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE UNDER 37 C.F.R. 1.10 ON THE DATE INDICATED ABOVE, AND IS ADDRESSED TO: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22201.

SUSAN FOUR | FOUNCISCO

ITYPO OF PRINTED NAME OF DERSON MAILING PAPER OR FEE!

SIGNATURE OF PERSON MAILING PAPER OR FEE!

## TRANSMITTAL

Responsive to the NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES mailed September 20, 2002, the following are provided:

- X (1) a copy of the Notice to Comply with a copy of the Raw Sequence Listing Error Report;
- X (2) a copy of the sequence listing in computer readable form;
- \_\_\_ (3) Communication;
- X (4) paper copy of sequence listing, pages 1 through 113;
- X (5) a statement under 37 CFR §1.821(f) and (g);
- $\underline{X}$  (6) a Petition for a one-month Extension of Time; and
- $\underline{X}$  (7) a check in the amount of \$55.00 to cover the fee for the one-month extension of time.

Please charge any additional fees or credit any overpayment to Deposit Account No. 03-0370. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Date: November 20, 2002

Astrid R. Spain

Registration No. 47,956 Telephone: (858) 535-9001

Facsimile: (858) 535-8949

CAMPBELL & FLORES LLP 4370 La Jolla Village Drive, 7<sup>th</sup> Floor San Diego, California 92122 USPTO CUSTOMER NO. 23601

<u>...</u>

Inventors: Rajotte et al.

Serial No.: 09/676,475 Filed:

September 29, 2000

Page 2

- \_\_ A check in the amount of \$ is enclosed, \$ covers the fee for a -month extension of time.
- $\underline{X}$  The Commissioner is hereby authorized to charge payment of any fees associated with this communication or credit any overpayment to Deposit Account No. 03-0370. A duplicate copy of this sheet is enclosed.
- $\underline{X}$  The Commissioner is hereby authorized to charge to Deposit Account No. 03-0370 any fees under 37 CFR 1.17 which may be required under 37 CFR 1.136(a)(3) for an extension of time in any concurrent or future reply requiring a petition for extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Astrid R. Spain

Registration No. 47,956 CAMPBELL & FLORES LLP 4370 La Jolla Village Drive 7<sup>th</sup> Floor San Diego, California 92122 858-535-9001

USPTO CUSTOMER NO. 23601



Application No.: 09/6 76, 475

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

	1.	This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
	2.	This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
X	3.	A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4.	A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5.	The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6.	The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	7.	Other:RECEIVE
		CLIVE
۸ "	1 i	NOV 2 ~ and
Ap	pli	icant Must Provide:
Ap	pli Ai	NOV 2 ~ and
<b>Ap</b>	Ai Ai	icant Must Provide:
Ap	Ai Ai A ap	icant Must Provide:  n initial or substitute computer readable form (CRF) copy of the "Sequence Listing". CENTER 1600 29  n initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry
	Ai in A ar 1.3	icant Must Provide:  In initial or substitute computer readable form (CRF) copy of the "Sequence Listing". CENTER 1600 29  In initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry to the specification.  In initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry to the specification.  In initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry to the specification.
D For	Ai in A ar 1.3	icant Must Provide: In initial or substitute computer readable form (CRF) copy of the "Sequence Listing". CENTER 1600 29  In initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry to the specification.  It is content of the "Sequence Listing", as well as an amendment directing its entry to the specification.  It is content of the paper and computer readable copies are the same and, where opplicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 825(b) or 1.825(d).  It is content that the content of the paper and computer readable copies are the same and, where opplicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 825(b) or 1.825(d).
For For	Ain A ar 1.3 q R	icant Must Provide:  In initial or substitute computer readable form (CRF) copy of the "Sequence Listing." CENTER 1600 29  In initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry to the specification.  In initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry to the specification.  In initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry to the specification.  In initial or substitute paper copy of the "Sequence Listing.", as well as an amendment directing its entry to the specification.  In initial or substitute paper copy of the "Sequence Listing." OF INSERTING INSTRUMENT OF INSERTING IN
For For	Ain A ar 1.3 q R	icant Must Provide:  In initial or substitute computer readable form (CRF) copy of the "Sequence Listing." CENTER 1600 29  In initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry to the specification.  In initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry to the specification.  In initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry to the specification.  In initial or substitute paper copy of the "Sequence Listing.", as well as an amendment directing its entry to the specification.  In initial or substitute paper copy of the "Sequence Listing." (Sequence Listing.)  In initial or substitute paper copy of the "Sequence Listing." (Sequence Listing.)  In initial or substitute paper copy of the "Sequence Listing." (Sequence Listing.)  In initial or substitute paper copy of the "Sequence Listing." (Sequence Listing.)  In initial or substitute paper copy of the "Sequence Listing." (Sequence Listing.)  In initial or substitute paper copy of the "Sequence Listing." (Sequence Listing.)  In initial or substitute paper copy of the "Sequence Listing." (Sequence Listing.)  In initial or substitute paper copy of the "Sequence Listing." (Sequence Listing.)  In initial or substitute paper copy of the "Sequence Listing." (Sequence Listing.)  In initial or substitute paper copy of the "Sequence Listing." (Sequence Listing.)  In initial or substitute paper copy of the "Sequence Listing." (Sequence Listing.)  In initial or substitute paper copy of the "Sequence Listing." (Sequence Listing.)  In initial or substitute paper copy of the "Sequence Listing." (Sequence Listing.)  In initial or substitute paper copy of the "Sequence Listing." (Sequence Listing.)  In initial or substitute paper copy of the "Sequence Listing." (Sequence Listing.)  In initial or substitute paper copy of the "Sequence Listing." (Sequence Listing.)  In initial or substitute paper copy of the "Sequence Listi

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE